These RFFL-targeting ASOs enhanced CFTR modulator efficacy by increasing functional CFTR in patient-derived bronchial epithelial cells, offering a promising nucleic acid-based therapeutic strategy for cystic fibrosis beyond current modulators. Here, CFTR is linked to cystic fibrosis.